For tumor-specific IL-2 delivery, an anti-VEGFR2 nanobody was fused with a mutant IL-2, creating a novel immunocytokine that retained antigen-selective targeting, activated peripheral blood mononuclear cells (PBMCs), and extended IL-2 half-life [221]. This evidence concerns the gene KDR and neoplasm.